Table 1.
Socio-demographic and clinical characteristics of the study patients at the time of starting the analytical treatment interruption.
| Patient 1 | Patient 2 | Patient 3 | |
|---|---|---|---|
| Gender | Female | Male | Male |
| Age (years) | 51 | 50 | 35 |
| Time of HIV infection (years) | 18 | 18 | 14 |
| Time on ART (years) | 9.75 | 16.83 | 8.50 |
| Current ART regimen | EFV + FTC + TDF | DRVr + FTC + TDF | EFV + FTC + TDF |
| Nadir CD4 (cells/µL) | 171 | 246 | 230 |
| CD4+ T cell counts (cells/µL) | 746 | 989 | 552 |
| CD8+ T cell counts (cells/µL) | 857 | 590 | 883 |
| CD4:CD8 Ratio | 0.8 | 1.6 | 0.6 |
| CD38+/HLA-DR+/CD4+ T cells (%) | 1.7 | 2.3 | 2.9 |
| CD38+/HLA-DR+/CD8+ T cells (%) | 2.1 | 2.9 | 5.6 |
| IUPM | < 0.012 | < 0.012 | < 0.012 |
| Episomal2 LTR DNA circles | Undetectable | Undetectable | Undetectable |
| HIV tropism | R5 | R5 | R5 |
ART antiretroviral treatment, DRVr ritonavir-boosted darunavir, EFV efavirenz, FTC emtricitabine, TDF tenofovir, IUPM infections units per million cells.